Business Context and Reporting Period
This Form 8-K is a current report filed by Millendo Therapeutics, Inc. (noted as Tempest Therapeutics in metadata) on March 22, 2019. The filing serves to update the company's corporate presentation, which is attached as Exhibit 99.1 and incorporated by reference.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is informational regarding a corporate presentation update and does not contain a financial statement or earnings release.
Material Changes
The only material event reported is the update to the company's corporate presentation on March 22, 2019. No financial or operational changes are detailed within the text of this specific filing.
Guidance, Outlook, and Risks
Management commentary, guidance, outlook, risks, contingencies, and unusual items are not explicitly detailed in the body of this Form 8-K. Investors are directed to the attached Corporate Presentation (Exhibit 99.1) for such information.
Investor Verification Checklist
- Review the attached Corporate Presentation (Exhibit 99.1) for updated business strategy, clinical trial data, and financial outlook.
- Verify the company name discrepancy between the metadata ("Tempest Therapeutics") and the filing ("Millendo Therapeutics, Inc.").
- Confirm the date of the corporate presentation update matches the filing date of March 22, 2019.